title: The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study.
abstract: BACKGROUND
  There has been some concern that leucotriene receptor antagonists might precipitate the onset of Churg-Strauss syndrome (CSS). A study was undertaken to investigate the relationship between the leucotriene receptor antagonist montelukast and the onset of CSS.
  
  
  METHODS
  Medication histories of 78 patients with CSS from France and Germany were retraced by questioning the patients, treating physicians and dispensing pharmacists, and from medical records. Using a case-crossover research design, exposures to montelukast and other asthma medications during the 3-month "index" period immediately preceding the onset of CSS were compared with those of four previous 3-month "control" periods. Odds ratios (ORs) were computed by conditional logistic regression.
  
  
  RESULTS
  The ORs for CSS onset were 4.5 (95% CI 1.5 to 13.9) for montelukast, 3.0 (95% CI 0.8 to 10.5) for inhaled long-acting beta(2) agonists, 1.7 (95% CI 0.5 to 5.4) for inhaled corticosteroids and 4.0 (95% CI 1.3 to 12.5) for oral corticosteroids. Montelukast exposure during control periods increased temporally over three consecutive calendar periods of CSS onset from 1999 to 2003 (p(trend) <0.0001).
  
  
  CONCLUSIONS
  Montelukast use was associated with a 4.5-fold higher risk of CSS onset within 3 months. However, the positive estimates obtained for other long-term asthma control medications suggest that this link might be confounded by a general escalation of asthma therapy before CSS onset. The association between montelukast and CSS observed in this study is probably also explained by the increasing use of this medication over time.
authors.affiliation: Department of Internal Medicine, Hôpital Cochin, 27 rue du Faubourg Saint-Jacques, 75679 Paris Cedex 14, France.
authors.forename: T
authors.initials: T
authors.lastname: Hauser
authors.forename: A
authors.initials: A
authors.lastname: Mahr
authors.forename: C
authors.initials: C
authors.lastname: Metzler
authors.forename: J
authors.initials: J
authors.lastname: Coste
authors.forename: R
authors.initials: R
authors.lastname: Sommerstein
authors.forename: W L
authors.initials: WL
authors.lastname: Gross
authors.forename: L
authors.initials: L
authors.lastname: Guillevin
authors.forename: B
authors.initials: B
authors.lastname: Hellmich
mesh_terms: D000085:Acetates / Q000009:adverse effects*; D000208:Acute Disease; D018927:Anti-Asthmatic Agents / Q000009:adverse effects*; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000378:metabolism; D001249:Asthma / Q000188:drug therapy*; D016022:Case-Control Studies; D015267:Churg-Strauss Syndrome / Q000139:chemically induced*; D018592:Cross-Over Studies; D003521:Cyclopropanes; D005260:Female; D006801:Humans; D020024:Leukotriene Antagonists / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000009:adverse effects*; D013440:Sulfides
chemical_list: D000085:Acetates; D018927:Anti-Asthmatic Agents; D019268:Antibodies, Antineutrophil Cytoplasmic; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast